MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Multi-Pathogen Vaccine Kit
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Multi-Pathogen Vaccine Kit
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • August 2018

AIVITA Biomedical Appoints Chief Financial Officer and Vice President of Business Development

AIVITA Biomedical Announces Initiation of First Clinical Site for ROOT OF CANCER Glioblastoma Trial

AIVITA Biomedical to Speak and Exhibit Skincare Products at August Aesthetics Conferences

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target infectious diseases and tumor-initiating cells — the seed of all cancers — using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
  • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress
  • AIVITA Biomedical Strengthens Board of Directors with Appointment of Ex-Biogen CEO Michel Vounatsos
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Present at Biotech Showcase 2024

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.